Do We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/8c/66/13/8c661348-6248-e8da-ba0e-e7ae01093499/mza_16547517506597716152.jpg/600x600bb.jpg

Market Pathways

33 episodes

2 days ago

Your premium guide to global medical device regulation, reimbursement and policy. Market Pathways delivers incomparable intelligence exploring the people, challenges, and opportunities impacting the global medtech regulatory and reimbursement community. View the latest issue of Market Pathways on MyStrategist.com

Business

RSS

All content for Market Pathways is the property of Market Pathways and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Business

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo400/16409909/16409909-1625152845569-6eabadc562071.jpg

Do We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan

Market Pathways

33 minutes 59 seconds

3 years ago

Do We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan

One of the hottest issues in medtech reimbursement is whether there is a need for an expedited reimbursement program following the repeal of MCIT. In this episode of the Market Pathways podcast, former CMS Administrator and FDA Commissioner Mark McLellan weighs in on this and other reimbursement and regulatory concerns facing the device industry.

#medtech #MedicalDevices #FDA #CMS #MCIT

View the latest issue of Market Pathways: https://bit.ly/3M4gsLc

View more podcast episodes: https://bit.ly/3vgFTlT

About Market Pathways